Rompag 50mg (Generic Revolade) Adelaide — Eltrombopag ITP & Aplastic Anaemia South Australia 2026

❓ FAQ 1: What is paroxysmal nocturnal haemoglobinuria (PNH) and how does it relate to aplastic anaemia managed with Rompag?

PNH (Paroxysmal Nocturnal Haemoglobinuria) is a clonal blood disorder caused by somatic mutation in the PIGA gene in haematopoietic stem cells, resulting in deficiency of GPI-anchored complement regulatory proteins on blood cell surfaces. Without these proteins, red blood cells, white cells, and platelets become vulnerable to destruction by complement — causing haemolytic anaemia, thrombosis, and cytopenias. PNH is intimately linked with aplastic anaemia — PNH clones are found in 40-60% of aplastic anaemia patients, arising because PIGA-mutant stem cells have a survival advantage in the immune-attack environment of aplastic anaemia. Adelaide's haematologists screen all aplastic anaemia patients for PNH by flow cytometry at diagnosis and during follow-up, as significant PNH clones (>10%) may require complement inhibitor therapy (Eculizumab or Ravulizumab) alongside Rompag-based immunosuppression.

❓ FAQ 2: How does the South Australian PBS process work for accessing Rompag for aplastic anaemia?

Eltrombopag (Rompag/Revolade) for aplastic anaemia in Australia is listed on the PBS under Highly Specialised Drugs — requiring prescribing through a specialist haematologist at an approved hospital facility. PBS criteria for aplastic anaemia require: confirmed diagnosis of severe or very severe aplastic anaemia, documentation of prior treatment with horse ATG (or bone marrow transplant not feasible), and specific haematological parameters confirming disease severity. The approval process involves haematologist application to Services Australia, typically with supporting bone marrow biopsy, flow cytometry, and blood count data. Adelaide's Royal Adelaide haematology team manages this approval process for all aplastic anaemia patients — private generic Rompag from Unnati Pharmax serves as bridging supply during approval processing periods, or for patients whose disease parameters narrowly miss PBS criteria but still have significant clinical need.

❓ FAQ 3: What is the role of bone marrow biopsy in monitoring aplastic anaemia treatment response with Rompag?

Bone marrow biopsy plays several important roles in monitoring aplastic anaemia treatment with Rompag-based immunosuppression at Adelaide's Royal Adelaide Hospital. Baseline biopsy confirms the diagnosis — characteristically showing hypocellular marrow with fatty replacement and residual normal marrow architecture, distinguishing aplastic anaemia from hypoplastic MDS or other marrow failure syndromes. Response assessment biopsy at 3-6 months demonstrates cellularity recovery — increasing marrow cellularity with return of normal haematopoietic elements indicates treatment success. Long-term surveillance biopsies detect clonal evolution — emergence of chromosomal abnormalities, MDS features, or blast increase that signal transformation, requiring treatment change. PNH clone monitoring by flow cytometry accompanies biopsy assessments. While peripheral blood counts (improving neutrophils, haemoglobin, platelets) provide practical real-world response evidence, bone marrow biopsy provides the definitive histological confirmation of marrow recovery that guides long-term treatment planning.

❓ FAQ 4: What support services are available in Adelaide for patients diagnosed with aplastic anaemia?

Aplastic anaemia is a relatively rare and often shocking diagnosis — patients are typically told their bone marrow has essentially stopped working, which is as alarming as it sounds. Adelaide's support resources for aplastic anaemia patients include: Leukaemia Foundation Australia (which covers aplastic anaemia and other bone marrow failure disorders despite its name), providing patient information, financial assistance, accommodation for interstate treatment, and peer support connections; South Australia-based Bone Marrow Failure Support Group connected through the Royal Adelaide haematology service; Macquarie University's Bone Marrow Failure Group (national research network) for patients interested in research participation; ISTH (International Society on Thrombosis and Haemostasis) patient resources; and My Cancer Navigator SA — a state-based service providing practical assistance with financial, transport, and accommodation challenges during intensive haematology treatment. Adelaide's Royal Adelaide social work team coordinates access to these resources for all newly diagnosed aplastic anaemia patients.

❓ FAQ 5: What is the long-term survival outlook for aplastic anaemia patients successfully treated with Rompag-based immunosuppression?

Long-term survival for aplastic anaemia patients successfully treated with immunosuppression including Eltrombopag (Rompag) has improved substantially over recent decades. For patients achieving complete haematological response (CR) — defined as normal or near-normal blood counts — with ATG + cyclosporine + Rompag combination, long-term survival now approaches 80-90% at 5 years in appropriately selected patient populations. Key prognostic factors include: age (younger patients do better), response depth (CR versus partial response), time to response (faster responders have better long-term outcomes), and absence of clonal evolution. The main long-term risks are relapse (occurring in 30-40% within 5 years, manageable with repeat IST or transplant), clonal evolution to MDS/AML (10-15% over 10 years, as discussed), and late infections from prolonged cyclosporine-associated immunosuppression. For patients who fail IST, allogeneic stem cell transplant salvage achieves 60-70% long-term survival — making even relapsed aplastic anaemia a potentially curable condition with modern treatment at Adelaide's Royal Adelaide Hospital.